All News

The U.S. FDA has granted fast track designation to the investigational therapy MNV-201 for the treatment of myelodysplastic syndrome.

Non-melanoma skin cancer is a common and highly treatable type of cancer that originates in the top layer of the skin, like basal cell carcinoma.

The FDA has granted approval to subcutaneous Keytruda for use in adults and pediatric patients with a solid tumor.

Many of the choices I've made regarding yard maintenance relate to my hopes to mitigate the risk of more cancer.

A guide for patients to understand HER2-positive breast cancer, treatment options by stage and how to talk with your oncologist.

Among patients with pancreatic cancer, the vaccine ELI-002 7P elicited strong mKRAS-specific T cell responses in approximately 99% of patients.

Obtaining an accurate diagnosis is a crucial first step in kidney cancer care, according to Dr. Shuanzeng “Sam” Wei of Fox Chase Cancer Center.

A cancer survivor explains that we must all become involved in trying to bring back cancer research.

Nancee Pronsati discusses a new patient-authored guide for managing ALK-directed treatment side effects in lung cancer and improving quality of life.

Leukemia is a blood cancer that disrupts normal cell production, leading to infection risk, anemia and bleeding, and requiring tailored treatments.

What is the first emotion that comes to mind about your cancer journey? For me, the strong emotion that I choose is shock!

Diagnosed with multiple myeloma? Our guide explains each stage and treatment, helping you engage confidently with your care team.

The FDA approved Bosaya and Aukelso, biosimilars of Prolia and Xgeva, respectively, for the treatment of solid tumors, like breast and prostate cancer.

Being diagnosed with a rare cancer like GIST can be overwhelming, highlighting the need for support networks, says Dr. Rosario Ligresti.

I reflect on how my family and friends showed love in different ways during the early days of my chronic cancer diagnosis.

Researchers have created a novel immunotherapy for metastatic kidney cancer that could provide a new treatment option for patients with limited options.

For patients with advanced GIST, complete surgical removal of metastases and full response to Gleevec are associated with roughly double the survival time.

Having been through two bouts of breast cancer, I am happy to be on this planet with my family, friends and neighbors.

Bob Lane, a prostate cancer survivor, discusses the stigma men often feel when talking about prostate cancer.

The FDA granted orphan drug designation to ligufalimab for AML, reflecting its potential as an immune-based therapy that may offer new options for patients.

Dr. Prithviraj Bose discusses how patients with myelofibrosis can better understand their options and access the most up-to-date advancements in care.

The first day of fall comes on September 22, and every year it feels like a reminder to pause.

Dr. Joshua K. Sabari sat down with Terri Conneran at the 2025 World Conference on Lung Cancer for a conversation on the importance of biomarker testing.

Dr. Prithviraj Bose explains how doctors tailor myelofibrosis treatments and how patients can work with their care teams to navigate options.

Since being diagnosed with breast cancer, my life has drastically changed. Time has helped each day become more precious and has caused me to become more grateful.

For patients with myelofibrosis, there is a risk of non-melanoma skin cancer or shingles among patients who received long-term treatment with Jakafi.

The FDA has granted fast track designation to the investigational drug CRB-701 for recurrent or metastatic head and neck squamous cell carcinoma.

Dr. Rosario Ligresti explained that while many GISTs are found incidentally, larger tumors may cause anemia, bleeding or swallowing issues.

Five years after being diagnosed with colon cancer, I would like to share how my support system continues to play a role in my life after active treatment.

Dr. Geoffrey Liu discussed findings from the phase 2 TRUST-II clinical trial evaluating Ibtrozi (taletrectinib) among patients with ROS1-positive non-small cell lung cancer.